Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Evoke H1 EBITDA jumps 44pc, pre-tax losses halve

(Sharecast News) - Betting and gaming group Evoke reported an improved first-half performance on Wednesday, with profitability and margin expansion helping offset modest top-line growth. Evoke said adjusted underlying earnings had jumped 44% year-on-year to £166m, driven by higher gross margins and reduced marketing spend, while reported EBITDA more than tripled to £141.3m, reflecting fewer exceptional costs linked to its US B2C exit in FY24 and transformation charges. Losses after tax improved by 55% to £64.7m, narrowing from £143.2m a year earlier.

Evoke said group revenues rose 3% to £887.8m, with international markets up 13% to £429.2m and UK&I online down 1% to £313.3m, impacted by tough comparatives and a shift in marketing strategy. Retail revenue dipped 2% to £145.3m but returned to growth in Q2.

Evoke, formerly known as 888 Holdings, also said it had made headway on deleveraging, cutting its net debt to EBITDA ratio by 1.7x to 5.0x.

CEO Per Widerström said: "Having delivered four consecutive quarters of growth, we are well positioned to drive continued progress, supported by our leading market positions, established brands, outstanding products, and a clear customer proposition.

"The acceleration in Q2 performance, together with a strong pipeline of product enhancements and operational efficiency initiatives, underpins our confidence of improved growth in H2 and reiterated guidance of 5-9% revenue growth and an Adjusted EBITDA margin of at least 20% in 2025, as we continue to execute against our plans to create significant shareholder value."

As of 0855 BST, Evoke shares were up 4.96% at 65.39p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.